We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Revance Therapeutics Inc | NASDAQ:RVNC | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.16 | -4.60% | 3.32 | 3.30 | 3.39 | 3.65 | 3.27 | 3.58 | 2,559,951 | 00:26:05 |
Delaware
(State or other jurisdiction of incorporation or organization) |
77-0551645
(I.R.S. Employer Identification No.) |
7555 Gateway Boulevard
Newark, California 94560 (Address of Principal Executive Offices) |
94560
(Zip Code) |
Large accelerated filer
¨
|
Accelerated filer
ý
|
Non-accelerated filer
¨
(Do not check if a smaller reporting company)
|
Smaller reporting company
¨
|
Emerging growth company
ý
|
|
Title of Securities
to be Registered |
|
Amount
to be Registered(1) |
|
Proposed
Maximum Offering Price per Share(2) |
|
Proposed
Maximum Aggregate Offering Price(2) |
|
Amount of
Registration Fee |
|||||||
Common Stock, par value $0.001 per share
|
|
|
|
|
|
|
|
|
|||||||
– 2014 Equity Incentive Plan
|
|
1,460,643
|
|
$
|
30.20
|
|
|
$
|
44,111,418.60
|
|
|
$
|
5,491.87
|
|
|
– 2014 Employee Stock Purchase Plan
|
|
300,000
|
|
$
|
30.20
|
|
|
$
|
9,060,000.00
|
|
|
$
|
1,127.97
|
|
|
Total
|
|
1,760,643
|
|
$
|
30.20
|
|
|
$
|
53,171,418.60
|
|
|
$
|
6,619.84
|
|
|
(1)
|
Pursuant to Rule 416 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of Registrant’s common stock that become issuable under the plans set forth herein by reason of any stock dividend, stock split, recapitalization, or other similar transaction effected that results in an increase to the number of outstanding shares of Registrant’s common stock.
|
||||||||||||||
(2)
|
Estimated in accordance with Rule 457(c) and Rule 457(h) promulgated under the Securities Act solely for the purpose of calculating the registration fee. The offering price per share and the aggregate offering price are based upon the average of the high and low prices of the Registrant’s common stock as reported on the Nasdaq Global Market on February 23, 2018, in accordance with Rule 457(c) of the Securities Act.
|
REVANCE THERAPEUTICS, INC.
|
||
|
|
|
By:
|
|
/s/ L. Daniel Browne
|
|
|
L. Daniel Browne
|
|
|
President and Chief Executive Officer
|
Signature
|
Title
|
Date
|
|
|
|
/s/ L. Daniel Browne
|
President, Chief Executive
|
March 2, 2018
|
L. Daniel Browne
|
Officer and Director
|
|
|
(Principal Executive Officer)
|
|
|
|
|
/s/ Lauren P. Silvernail
|
Chief Financial Officer and
|
March 2, 2018
|
Lauren P. Silvernail
|
Chief Business Officer
|
|
|
(Principal Financial and Accounting Officer)
|
|
|
|
|
/s/ Angus C. Russell
|
Director, Chairman
|
March 2, 2018
|
Angus C. Russell
|
|
|
|
|
|
/s/ Robert Byrnes
|
Director
|
March 2, 2018
|
Robert Byrnes
|
|
|
|
|
|
/s/ Mark Foley
|
Director
|
March 2, 2018
|
Mark Foley
|
|
|
|
|
|
/s/ Phyllis Gardner
|
Director
|
March 2, 2018
|
Phyllis Gardner, M.D.
|
|
|
|
|
|
/s/ Julian S. Gangolli
|
Director
|
March 1, 2018
|
Julian S. Gangolli
|
|
|
|
|
|
/s/ Philip J. Vickers
|
Director
|
March 1, 2018
|
Philip J. Vickers, Ph.D.
|
|
|
Exhibit
Number
|
|
Exhibit Description
|
|
Incorporated by Reference to the Company's
|
|
Filed
Herewith
|
||||||
Form
|
|
File No.
|
|
Exhibit No.
|
|
Filed On
|
||||||
4.1
|
|
|
8-K
|
|
001-36297
|
|
3.1
|
|
February 11, 2014
|
|
|
|
4.2
|
|
|
S-1
|
|
333-193154
|
|
3.4
|
|
December 31, 2013
|
|
|
|
4.3
|
|
|
S-1/A
|
|
333-193154
|
|
4.4
|
|
February 3, 2014
|
|
|
|
4.4
|
|
|
S-1
|
|
333-193154
|
|
10.5
|
|
January 27, 2014
|
|
|
|
4.5
|
|
|
10-K
|
|
001-36297
|
|
10.6
|
|
March 4, 2016
|
|
|
|
4.6
|
|
|
10-Q
|
|
001-36297
|
|
10.3
|
|
November 10, 2015
|
|
|
|
4.7
|
|
|
10-K
|
|
001-36297
|
|
10.8
|
|
March 4, 2016
|
|
|
|
4.8
|
|
|
S-1
|
|
333-193154
|
|
10.7
|
|
January 27, 2014
|
|
|
|
5.1
|
|
|
|
|
|
|
|
|
|
|
X
|
|
23.1
|
|
|
|
|
|
|
|
|
|
|
X
|
|
23.2
|
|
|
|
|
|
|
|
|
|
|
X
|
|
24.1
|
|
|
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 Year Revance Therapeutics Chart |
1 Month Revance Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions